Skip to content
Menu

SpyGlass Pharma, Inc. SGP

Full chart Compare
Set alert

Price alert · SGP

All alert types
30.43 USD -0.35 (-1.14%)

Regular-session close

30.43 0.00 0.00%

After hours · Nov 20, 4:01 PM ET

29.60 Day range 31.73
17.56 52-week range 38.37
YTD
+15.27%
1 year
+15.27%

5D -1.14 (-3.51%)

283032MonTueWedThuFri31.34
Market cap
1.02B
EPS (ttm)
-2.70
Shares out
33.46M
Forward P/E
-10.04
YTD return
+15.27%
1-year return
+15.27%
50-day average
29.01
200-day average
25.02
Enterprise value
815.79M
Volume
108.91K
Avg volume
113.74K
Open
30.12
Previous close
30.78
Day's range
29.60 – 31.73
52-week range
17.56 – 38.37
Analysts
Strong Buy
Price target
46.67 (+53.4%)
Earnings date
Mar 25, 2027

Key statistics

Price / book
4.84
Free cash flow
-37.95M
Total cash
215.76M
Total debt
1.61M
Return on equity
-43.01%
Short % of float
10.44%

Fundamental scorecard

4 of 25 checks passed on SGP’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
SGP Revenue — quarterly 0
SGP Net income — quarterly -24.25M
SGP EPS — quarterly -0.73

Earnings

SGP recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 25, 2027Dec 30, 2026-0.77———
Nov 11, 2026Sep 30, 2026-0.62247-0.73-0.11-17.27%
Aug 6, 2026Jun 30, 2026-0.51442-0.59-0.08-14.69%
May 15, 2026Mar 31, 2026-0.67-0.69-0.02-2.99%
Mar 26, 2026Dec 31, 2025-0.57422-5.72-5.15-896.13%
Dec 3, 2025Sep 30, 2025—-0.44776——

Upgrades / downgrades

SGP analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2026CitigroupmainBuyBuy
Nov 13, 2026StifelmainBuyBuy
Nov 12, 2026HC Wainwright & Co.mainBuyBuy
Oct 21, 2026HC Wainwright & Co.reitBuyBuy
Oct 5, 2026HC Wainwright & Co.reitBuyBuy
Aug 14, 2026Raymond Jamesinit—Outperform

About SpyGlass Pharma, Inc.

SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intraocular pressure (IOP) in patients. It also develops a non-IOL-based, ring-shaped, sustained-release implant with bimatoprost. SpyGlass Pharma, Inc. was formerly known as SpyGlass Ophthalmics, Inc. and changed its name to SpyGlass Pharma, Inc. in April 2021. The company was headquartered in 2019 and is based in Irvine, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on SGP — it syncs with the Stock Master app.

Insider holders

SGP insider holders
InsiderRelationLatest transactionDateShares held
BASKETT FORESTBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260
BEHBAHANI ALIDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260
CHANG CARMENBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260
FLORENCE ANTHONY A JRBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260
MAKHZOUMI MOHAMADBeneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260
MATHERS EDWARD T.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityFeb 8, 20260

Institution ownership

SGP institution ownership
Holder% heldSharesValueReported
RA Capital Management, L.P.23.97%8,021,117244.08MSep 29, 2026
NEA Management Company, LLC22.09%7,392,301224.95MSep 29, 2026
Sands Capital Alternatives, LLC7.47%2,500,01276.08MSep 29, 2026
Samsara BioCapital, LLC6.31%2,109,95364.21MSep 29, 2026
JPMORGAN CHASE & CO3.00%1,003,26830.53MSep 29, 2026
Price (T.Rowe) Associates Inc2.77%925,76728.17MSep 29, 2026

Fund ownership

SGP fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund0.95%317,0539.65MJun 29, 2026
JPMorgan Trust II-JPMorgan Small Cap Growth Fund0.87%291,2728.86MJun 29, 2026
T. Rowe Price Health Sciences Fund, Inc.0.74%247,1967.52MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF0.73%245,0447.46MSep 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.69%229,7066.99MJun 29, 2026
abrdn Healthcare Investors0.64%214,4736.53MJun 29, 2026